| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afd115dec46c157d3739020ebd4d866b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d8881aa98b7ef4758d08669e3fd80b96 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2016-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_daa449906765b93768c11761aadce1d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25630f0078342df65c4e9cbe21268bd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1dbe374d4f0f38ac0504e476f254dca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aab024c358a6a3accafb21abbfdd5db3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_439204215f38a840852a09d4d436b99c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_954c6ecf35db0633bae4ff160734c628
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d93424fe95d04f486acac611aff6ecf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_db7939d0fef119e645793a0fcf89ef25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6915757e2b046623ce2875d87fcad664 |
| publicationDate |
2017-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20170083914-A |
| titleOfInvention |
Pharmaceutical composition for treatment of cancer comprising antibody specifically binding to epidermal growth factor receptor |
| abstract |
The present invention relates to a composition for treating cancer or a therapeutic method comprising an antibody that specifically binds to a epidermal growth factor receptor as an active ingredient. The composition for treating cancer according to the present invention exhibits an activity of inhibiting the growth of tumor cells having resistance to cetuximab, which has been conventionally used as an anticancer agent. Therefore, the above composition can be usefully used for the treatment of cancer, particularly cancer resistant to anticancer agents. |
| priorityDate |
2016-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |